LENZ Therapeutics and Laboratoires Théa Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada

Core Insights - LENZ Therapeutics and Laboratoires Théa have entered into an exclusive license and commercialization agreement for LNZ100, aimed at treating presbyopia in Canada, which includes over $70 million in upfront and milestone payments along with double-digit royalties on net sales [1][2][3] Company Overview - LENZ Therapeutics is a pre-commercial biopharmaceutical company focused on developing the first aceclidine-based eye drop for improving near vision in presbyopia patients, with a PDUFA date set for August 8, 2025 [1][5] - Théa is an independent pharmaceutical company specializing in eye-care products, with a strong international presence and reported revenues of €970 million in 2024 [6] Market Potential - Presbyopia affects approximately 1.8 billion people globally and 128 million in the United States, indicating a significant market opportunity for LNZ100 [4][5] - The partnership with Théa is expected to enhance patient access to LNZ100 in Canada, a key market for Théa's international development [3][4]